HDAC Inhibitors

Histone Deacetylase (HDAC) Inhibitors

Introduction

```mermaid
flowchart TD
classDef gene fill:#0a1f0a,stroke:#4caf50
classDef protein fill:#0a1929,stroke:#2196f3
classDef disease fill:#2d0f0f,stroke:#e91e63
classDef pathway fill:#3e2200,stroke:#ff9800
classDef mechanism fill:#1a0a1f,stroke:#9c27b0
classDef therapeutic fill:#e0f2f1,stroke:#009688
HDAC_Inhibitors["HDAC Inhibitors"] -->|"treats"| Alzheimer_s_Disease["Alzheimer's Disease"]
HDAC_Inhibitors["HDAC Inhibitors"] -.->|"inhibits"| Amyloid_Beta_Plaque_Formation["Amyloid Beta Plaque Formation"]
HDAC_Inhibitors["HDAC Inhibitors"] -.->|"inhibits"| Tau_Protein_Phosphorylation["Tau Protein Phosphorylation"]
HDAC_Inhibitors["HDAC Inhibitors"] ==>|"upregulates"| Microtubule_Stability["Microtubule Stability"]
HDAC_Inhibitors["HDAC Inhibitors"] -.->|"inhibits"| Neuroinflammation["Neuroinflammation"]
HDAC_Inhibitors["HDAC Inhibitors"] ==>|"upregulates"| Cell_Survival["Cell Survival"]
HDAC_Inhibitors["HDAC Inhibitors"] -->|"modulates"| Blood_Brain_Barrier_Penetration["Blood-Brain Barrier Penetration"]
HDAC_Inhibitors["HDAC Inhibitors"] -->|"treats"| Neurological_Diseases["Neurological Diseases"]
HDAC_Inhibitors["HDAC Inhibitors"] -.->|"inhibits"| HDAC["HDAC"]
HDAC_Inhibitors["HDAC Inhibitors"] -->|"modulates"| Transcriptional_Repression["Transcriptional Repression"]
HDAC_Inhibitors["HDAC Inhibitors"] -->|"treats"| Nervous_System_Diseases["Nervous System Diseases"]
HDAC_Inhibitors["HDAC Inhibitors"] -->|"references"| HDAC["HDAC"]
HDAC_Inhibitors["HDAC

...

Histone Deacetylase (HDAC) Inhibitors

Introduction

Hdac Inhibitors is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Histone deacetylase (HDAC) inhibitors are a class of epigenetic drugs that modify gene expression by inhibiting histone deacetylases. [HDAC](/entities/hdac-enzymes) inhibitors have shown promise in treating neurodegenerative diseases by reducing protein aggregation, improving mitochondrial function, and modulating neuroinflammation. [@xu2011]

Overview

HDAC Biology

Classes of HDACs

• Class I (HDAC1, 2, 3, 8): Nuclear enzymes, ubiquitously expressed
• Class IIa (HDAC4, 5, 7, 9): Tissue-specific, can shuttle to cytoplasm
• Class IIb (HDAC6, 10): Cytoplasmic, mainly non-histone targets
• Class III (SIRT1-7): NAD+-dependent, see Sirtuin Modulators
• Class IV (HDAC11): Brain-enriched

Mechanism of Action

HDAC inhibitors work through:

Histone hyperacetylation: Increased chromatin accessibility for transcription

Non-histone targets: Acetylation of transcription factors, chaperones

Gene expression modulation: Upregulation of neuroprotective genes

Protein clearance: Enhanced [autophagy](/entities/autophagy) and proteasome function

Therapeutic Applications

Alzheimer's Disease

HDAC inhibitors benefits:

• Enhanced memory and synaptic plasticity
• Reduced [amyloid-beta](/proteins/amyloid-beta) production
• Improved [tau](/proteins/tau) pathology
• Enhanced mitochondrial function
• Reduced neuroinflammation

Key drugs: Vorinostat, Valproic acid, Sodium butyrate

Parkinson's Disease

Benefits:

• Protection of dopaminergic [neurons](/entities/neurons)
• Reduced [α-synuclein](/proteins/alpha-synuclein) aggregation
• Enhanced autophagy
• Improved mitochondrial function

Huntington's Disease

Benefits:

• Reduced mutant [huntingtin](/proteins/huntingtin-protein) aggregation
• Improved neuronal survival
• Enhanced transcription of neuroprotective genes
• Better motor function

Key drug: Valproic acid (in trials)

ALS

Benefits:

• Reduced [TDP-43](/proteins/tdp-43) aggregation
• Improved mitochondrial function
• Enhanced autophagy
• Delayed disease progression

FTD

Benefits:

• Reduced [tau](/proteins/tau) pathology
• Improved behavioral symptoms
• Enhanced synaptic function

Drug Candidates

| Compound | Class | Company | Status | Indication |
|----------|-------|---------|--------|----------|
| Valproic acid | HDAC I/IIa | Generic | Approved | Epilepsy, bipolar |
| Vorinostat | HDAC I/II | Merck | Approved | CTCL |
| Romidepsin | HDAC I | Celgene | Approved | CTCL |
| Panobinostat | HDAC I/II | Novartis | Approved | Multiple myeloma |
| TSA | HDAC I/II | N/A | Preclinical | N/A |
| SAHA | HDAC I/II | N/A | Preclinical | N/A |

Clinical Trials

• NCT00105547: Valproic acid for Alzheimer's disease (completed)
• NCT00105547: HDAC inhibitors in various neurodegenerative trials
• NCT03056473: Panobinostat for ALS (completed)

Challenges and Limitations

[BBB](/entities/blood-brain-barrier) penetration: Ensuring adequate CNS delivery

Off-target effects: Broad epigenetic changes

Side effects: Hematologic toxicity, fatigue

Patient selection: Identifying responders

Future Directions

• Selective HDAC6 inhibitors for neurodegeneration
• Brain-penetrant HDAC inhibitors
• Combination with other therapies
• Biomarker-driven patient selection

See Also

• [Epigenetics in Neurodegeneration](/mechanisms/epigenetics-ad)
• [Chromatin Remodeling](/mechanisms/chromatin-remodeling)
• [Transcription Regulation](/mechanisms/transcription-regulation)
• [Gene Expression Dysregulation](/mechanisms/gene-expression-dysregulation)
• [Alzheimer's Disease](/diseases/alzheimers-disease)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Hdac Inhibitors has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

References

[Gräff J, et al, (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22495356/)

[Xu K, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21549752/)

[Gray SG, et al, (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32531543/)

[Chuang DM, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19686132/)

[Konsoula Z, et al, (2011) (2011)](https://pubmed.ncbi.nlm.nih.gov/21881563/)

[Faraco G, et al, (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16534541/)

[Saha RN, et al, (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19650737/)

[Chen SH, et al, (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/26401515/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Astrocyte-Mediated Neuronal Epigenetic Rescue](/hypothesis/h-8fe389e8) — <span style="color:#81c784;font-weight:600">0.64</span> · Target: HDAC
• [Selective HDAC3 Inhibition with Cognitive Enhancement](/hypothesis/h-0e675a41) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: HDAC3
• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Tau-Independent Microtubule Stabilization via MAP6 Enhancement](/hypothesis/h-e12109e3) — <span style="color:#81c784;font-weight:600">0.67</span> · Target: MAP6
• [HDAC3-Selective Inhibition for Clock Reset](/hypothesis/h-a9571dbb) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: HDAC3
• [Temporal TET2-Mediated Hydroxymethylation Cycling](/hypothesis/h-a90e2e89) — <span style="color:#81c784;font-weight:600">0.61</span> · Target: TET2
• [Glial Glycocalyx Remodeling Therapy](/hypothesis/h-c35493aa) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: HSPG2
• [Partial Neuronal Reprogramming via Modified Yamanaka Cocktail](/hypothesis/h-baba5269) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: OCT4

Related Analyses:

• [Epigenetic reprogramming in aging neurons](/analysis/SDA-2026-04-02-gap-epigenetic-reprog-b685190e) &#x1f504;
• [Perivascular spaces and glymphatic clearance failure in AD](/analysis/SDA-2026-04-01-gap-v2-ee5a5023) &#x1f504;
• [Epigenetic clocks and biological aging in neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-bc5f270e) &#x1f504;